Phreesia, Inc. (PHR) Q2 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary highlights strong financial metrics, optimistic guidance, and strategic acquisitions like AccessOne, which align with market expansion and product development goals. The Q&A session revealed analyst confidence in AI integration and new product offerings, despite some uncertainty regarding specific revenue details. The company's market cap suggests a moderate reaction, leading to a positive stock price movement prediction of 2% to 8% over the next two weeks.
Key Financial Performance
Total Revenue $117.3 million, an increase of 15% year-over-year. The increase was attributed to strong performance on the top line.
Average Health Care Services Clients (AHSCs) 4,467, an increase of 56 AHSCs from the prior quarter and 298 in the prior year. This growth was in line with expectations.
Revenue per Average Health Care Services Client $26,249, up 7% year-over-year and flat quarter-over-quarter. This was also in line with expectations.
Net Income $700,000, marking the first-ever positive net income quarter for the company. This milestone reflects the strength of the business and financial model.
Adjusted EBITDA $22 million, an increase of $16 million year-over-year, with an adjusted EBITDA margin of 19%. This improvement highlights strong profitability growth.
Cash and Cash Equivalents $98.3 million, compared to $90.9 million in the prior quarter. This increase reflects improved cash management.
Operating Cash Flow $14.8 million, up $3.8 million year-over-year. This growth demonstrates continued operational efficiency.
Free Cash Flow $9.6 million, up $6 million year-over-year. This marks the fourth consecutive quarter of positive free cash flow.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Acquisition of AccessOne: Phreesia announced a definitive agreement to acquire AccessOne for $160 million. This acquisition is expected to expand Phreesia's addressable market by $6 billion and contribute approximately $35 million in annualized revenue and $11 million in annualized adjusted EBITDA. The acquisition complements Phreesia's payment strategy and strengthens its ability to help providers improve collections while preserving patient trust.
Expansion of Total Addressable Market (TAM): The AccessOne acquisition is expected to expand Phreesia's TAM by $6 billion in the payment solutions space. Additionally, the network solutions TAM increased by $6 billion due to a larger pool of life sciences marketing dollars. Combined, the TAM is expected to grow from $10 billion to $24 billion.
Revenue Growth: Total revenue for Q2 FY2026 was $117.3 million, a 15% year-over-year increase. Average revenue per healthcare services client was $26,249, up 7% year-over-year.
Profitability Milestone: Phreesia achieved positive net income for the first time in its history, with $700,000 in net income for Q2 FY2026. Adjusted EBITDA was $22 million, a $16 million year-over-year increase, with a 19% adjusted EBITDA margin.
Cash Flow Improvements: Operating cash flow was $14.8 million, up $3.8 million year-over-year. Free cash flow was $9.6 million, up $6 million year-over-year. Positive operating and free cash flow have been achieved for four consecutive quarters.
Leadership Appointments: Evan Roberts and David Linetsky were named President of Provider Solutions and Network Solutions, respectively, reflecting their leadership roles and contributions to Phreesia's mission.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Acquisition Financing Risks: The acquisition of AccessOne for $160 million will be financed through a combination of cash from the balance sheet and a new fully committed bridge loan facility. This introduces financial risks, including potential strain on cash reserves and increased debt obligations.
Regulatory Approval Risks: The AccessOne transaction is subject to customary closing conditions and regulatory approvals, which could delay or prevent the acquisition from being finalized.
Integration Challenges: Post-acquisition, integrating AccessOne into Phreesia's operations may present challenges, including aligning systems, processes, and cultures, which could impact operational efficiency and financial performance.
Revenue Dependency Risks: The company’s updated total addressable market (TAM) expansion relies heavily on the success of the AccessOne acquisition and the ability to draw from a larger pool of life sciences marketing dollars. Failure to achieve these goals could limit revenue growth.
Cash Flow Variability: The company acknowledges variability in cash flow improvements on a quarter-to-quarter basis due to timing of invoicing, payments, and CapEx, which could impact financial stability.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Outlook: Phreesia is maintaining its revenue outlook for fiscal year 2026 at a range of $472 million to $482 million.
Adjusted EBITDA Outlook: The adjusted EBITDA outlook for fiscal year 2026 has been updated to a range of $87 million to $92 million, an increase of $2 million at both the top and bottom ends of the previous range.
Acquisition Impact: The acquisition of AccessOne is expected to close during the third or early fourth quarter of fiscal year 2026. AccessOne is projected to contribute approximately $35 million in annualized revenue and $11 million in annualized adjusted EBITDA. The fiscal 2026 outlook will be updated post-acquisition to reflect its contribution.
Total Addressable Market (TAM) Expansion: The AccessOne acquisition is expected to expand Phreesia's addressable market by $6 billion. Additionally, the network solutions TAM is expected to increase by $6 billion, bringing the total TAM to approximately $24 billion from $10 billion.
Average Healthcare Services Clients (AHSCs): Phreesia reiterates its outlook to reach approximately 4,500 AHSCs in fiscal year 2026, with total revenue per AHSC expected to increase compared to fiscal year 2025.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How did the deal with AccessOne develop over time, and why is it considered the right asset and market for the company?
A:The company has been observing the space and AccessOne for years, knowing the company and its executives well. They felt confident due to product and regulatory requirements aligning with customer needs. The acquisition aligns with their mission of making care easier and was a well-considered decision over three years.
Q:How will the Phreesia VoiceAI product drive opportunities in the Network Solutions business?
A:The VoiceAI product benefits both providers and patients, creating more engagement opportunities for Network Solutions revenue. The product has been well-received by providers, and its applications are expected to grow in the coming quarters. The timing of its introduction is not directly linked to the TAM increase.
Q:Where does the VoiceAI product sit between a call center answering service and a nurse triage line, and can it handle more clinical questions over time?
A:The VoiceAI product already provides significant value to doctors and call centers, assisting with prescription refills, appointment booking, and other scenarios. It is expected to handle more clinical questions over time.
Q:Are the new products (VoiceAI, AI referrals, auto network tags) on a no-risk, no-cost model, and when will they positively impact revenue?
A:Yes, all new products are on a no-risk, no-cost model initially. Over time, these products are expected to have a material impact on revenue and client productivity, contributing to the company's core value proposition.
Q:What are the opportunities for Network Solutions with the AccessOne acquisition?
A:AccessOne aligns with the TAM increase in the Payment Solutions category, estimated at $6 billion. It has a strong footprint in health systems and medical groups, offering more touchpoints with patients in the payment process and potential incremental revenue opportunities.
Q:Who bears the risk for payment extensions to patients under AccessOne?
A:Phreesia does not bear the risk. The risk is shared between PNC Bank and the provider, with Phreesia focusing on providing robust payment solutions to patients.
Q:What is the mix of revenue for AccessOne between interest from payment plans and fees for 0% interest rate plans?
A:The transaction has not closed, so detailed revenue mix information is not available. The company plans to discuss this further after the transaction closes.
Q:What is the balance between investing in internal and external AI tools, and how are new AI products priced?
A:The company invests in both internal and external AI tools, focusing on building valuable products for clients. Monetization is secondary to creating value, and AI products are already being monetized.
Q:What is AccessOne's market share and positioning relative to other players in the patient financing services category?
A:AccessOne is ranked #3 or #4 in the patient financing services category. Its $35 million revenue is relatively small within a $6 billion TAM, but the company plans to invest in and grow its market share.
Q:What is the visibility for Network Solutions for the rest of the year and progress on pharma advertising upsell?
A:The company is in a similar position as last year at this time, with good progress on pharma advertising upsell. Updates will be provided in December.
Q:What are the drivers for reacceleration of growth in Network Solutions?
A:Growth is driven by increased relationships and campaigns sold throughout the year. The team is performing well, and the company is confident in its progress.
Q:What is the customer overlap between Phreesia's intake solutions and AccessOne's customers?
A:There is some customer overlap, as indicated by a client mentioned in the press release. More details will be provided after the transaction closes.
Q:What is the AI competitive landscape, and how is Phreesia monetizing AI solutions?
A:The market for AI solutions is massive, with significant customer interest. Phreesia is already monetizing its AI products, which are considered game-changing by customers.
Q:What was the impact of repurposing R&D tools to revenue-generating activities?
A:This was a one-off event that contributed to productivity. The company continues to invest significantly in R&D.
Q:Review of Unclear Management Responses
A:Management avoided providing direct answers or lacked clarity on the following questions: 1. The mix of revenue for AccessOne between interest and fees for 0% interest rate plans, citing the transaction has not closed. 2. Historical growth rates of AccessOne and whether Phreesia can accelerate its growth, stating they cannot provide historical numbers. 3. Specific examples or details on why VoiceAI drives a $6 billion TAM increase, citing competitive reasons. 4. Detailed customer overlap between Phreesia and AccessOne, deferring until after the transaction closes.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AccessOne Phreesia
AccessOne market
AccessOne progress
AccessOne transaction
Co Founder
Conference today
Founder Linetsky
Linetsky President
Mr today
Network Solutions
Phreesia Instructions
Phreesia agreement
Phreesia close
Phreesia milestone
Phreesia product
President Provider
Provider Network
Provider Solutions
Relations website
Solutions Network
Solutions team
Solutions title
ability provider
accomplishment power
acquisition Forward
acquisition extension
agreement AccessOne
approach gap
capital Co
care mission
care provider
client mission
detail
income
PHR Transcript
Phreesia, Inc. (PHR) Q1 2027 Earnings Call Transcript
Unknown5-27
The earnings call indicates strong revenue growth and improved gross margins, which are positive signs. However, the guidance for fiscal year 2027 has been revised downwards, which could negatively impact investor sentiment. The company's net loss has decreased, and cash flow has improved, but operating expenses have increased. The lack of discussion on shareholder returns and the absence of clear responses in the Q&A add uncertainty. Given these mixed signals and the company's small-cap status, the stock is likely to remain stable in the near term, resulting in a neutral sentiment.
Phreesia, Inc. (PHR) Q4 2026 Earnings Call Transcript
Positive3-31
The earnings call presented a mixed but generally positive outlook. The company achieved positive GAAP net income for the first time, showing profitability. Despite revenue reductions, the confidence in maintaining EBITDA guidance and ongoing margin expansion is promising. The strategic focus on AI, integration of AccessOne, and growth in Network Solutions and organic payments are positive indicators. While there are concerns about client spending and GLP-1 drugs, the overall sentiment and strategic direction suggest a likely positive stock price movement, especially for a small-cap stock with a market cap of $1.2 billion.
Phreesia, Inc. (PHR) Q3 2026 Earnings Call Transcript
Positive12-8
The earnings call presents strong financial metrics, including consecutive positive net income and increased cash flow, which are positive indicators. The Q&A session highlights a cautious but optimistic outlook, with plans for strategic investments and growth. While some management responses lack clarity, the overall sentiment is positive due to strong cash flow, margin expansion, and growth potential from acquisitions. The market cap suggests a moderate reaction, leading to a positive stock price movement prediction.
Phreesia, Inc. (PHR) Q2 2026 Earnings Call Transcript
Positive9-4
The earnings call summary highlights strong financial metrics, optimistic guidance, and strategic acquisitions like AccessOne, which align with market expansion and product development goals. The Q&A session revealed analyst confidence in AI integration and new product offerings, despite some uncertainty regarding specific revenue details. The company's market cap suggests a moderate reaction, leading to a positive stock price movement prediction of 2% to 8% over the next two weeks.
PHR Slides
PHR Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
